脱水胺酸:一种潜在的葡萄糖皮质体受体激动剂,具有抗coxsackievirus活性
Jieyu Li1, Yuanyuan Huang1, Qiting Luo2
1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China; College of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, PR China.
概括
脱水胺酸 (DA) 通过激活葡萄糖皮质体受体 (GR) 来表现出强大的抗病毒活性,对抗可萨基病毒血清型. 这种天然化合物具有抑制病毒复制和减少炎症的双重好处,解决了对有效疗法的关键需求.
科学领域:
- 病毒学 病毒学
- 自然产品化学 自然产品化学
- 免疫学 免疫学 免疫学
背景情况:
- 由于高突变率和多种血清型,Coxsackievirus感染构成了重大的公共卫生挑战,目前没有疫苗或治疗方法.
- 三聚类,天然化合物,具有抗病毒和免疫调节性质,提供潜在的治疗途径.
研究的目的:
- 评估脱水胺酸 (DA) 的抗病毒功效,这是来自Poria cocos的三烯酸,对各种Coxsackievirus血清型.
- 阐明DA抗病毒作用的作用机制.
主要方法:
- 为了评估病毒复制,使用了包括细胞病变效应抑制,qRT-PCR,西部斑块和斑块试验在内的体外抗病毒试验.
- 转录基因分析和细胞热转移试验被用来研究DA的作用机制.
- 抗病毒活性被测试对多个coxsackievirus血清型,包括CVB3.
主要成果:
- DA对可萨基病毒B1,B2,B3,A16和A6表现出显著的抗病毒活性,以剂量依赖的方式减少病毒复制,mRNA和蛋白质合成,没有细胞毒性.
- DA通过结合和激活葡萄糖皮质体受体 (GR) 起作用,该受体抑制MAPK/ERK信号传递,并减少促炎性细胞因子的产生.
- 与已知GR激动剂德甲相比,DA的抗病毒和抗炎作用更持久.
结论:
- 脱水胺酸 (DA) 是一个有前途的宿主向抗病毒药物,用于治疗 Coxsackievirus 感染,解决了关键的未满足需求.
- 通过GR激活,DA具有强大的抗病毒活性和抗炎作用的双重作用,提供了一种新的治疗策略.
- DA代表了进一步开发作为治疗萨克病毒相关疾病的有希望的候选人.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
397
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
397
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
263
Antiasthma Drugs: Muscarinic Receptor Antagonists
463
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
463


